Anixa Biosciences (ANIX) Non-Current Debt (2010 - 2017)

Anixa Biosciences' (ANIX) quarterly Non-Current Debt came in at $3.0 million in Q1 2017, down 40.0% on a QoQ basis from $5.0 million in Q4 2013.

Anixa Biosciences (ANIX) Non-Current Debt (2010 - 2017) Analysis & Trends

Anixa Biosciences (ANIX) has 5 years of Non-Current Debt data on file, last reported at $3.0 million in Q1 2017.

Quarterly Non-Current Debt changed N/A year-over-year to $3.0 million in Q1 2017, while the trailing twelve-month figure through Jan 2017 was $3.0 million (changed N/A YoY) and the FY2013 annual result came in at $5.0 million, changed 0.0% from the prior year.
Non-Current Debt declined to $3.0 million in Q1 2017, from $5.0 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $5.0 million in Q1 2013 to a low of $3.0 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-	-

Download Data